Commentary

HPV infection: in need of timely intervention

Ankit Chaudhary¹, Vijay K. Barwal¹*, Shaina Chamotra², Anjali Mahajan¹

¹Department of Community Medicine, ²Department of Obstetrics and Gynaecology, Indira Gandhi Medical College Shimla, Himachal Pradesh, India

Received: 01 September 2018
Accepted: 01 October 2018

*Correspondence:
Dr. Vijay K. Barwal,
E-mail: barwalvk@gmail.com

ABSTRACT

Persistent infection with human papilloma virus (HPV) has been proved beyond doubt to be associated with the development of cervical cancer. One woman dies of cervical cancer every 8 minutes in India. As per estimations for the year 2018, about 96922 new cervical cancer cases are diagnosed annually in India and it ranks as the second most common female cancer in all age groups. But being an infectious cause it is possible to contain its development and transmission. Coupled with this, we have a potent vaccine to fight this infection. A well documented account of positive impact of HPV vaccination has been published in numerous studies around the globe. By 2013, its vaccination had been introduced in about fifty countries around the globe. In India also, recently, two HPV vaccination projects for operational feasibility were launched in Andhra Pradesh and Gujarat. In November 2016, Punjab became the first state in the country to include the vaccine in its universal immunization program. This era belongs to women empowerment and we cannot deny them the opportunity of good health. Hence it’s high time India introduces an effective HPV vaccination program.

Keywords: HPV infection, Cervical cancer, HPV vaccine

INTRODUCTION

Human papilloma virus (HPV) is a sexually transmitted virus and its association with chronic diseases has been well documented.¹ Although majority of its infections are benign and transient, but persistent infection with HPV is associated with development of cervical cancer. Moreover there is growing evidence of HPV being a relevant factor in other anogenital cancers like anus, vulva, vagina and penis, as well as head and neck cancers.² Its association with cervical cancer in particular has been proved scientifically beyond any reasonable doubt.

BURDEN

All sexually active women are infected with HPV at least once during their lifetime, and the highest prevalence is seen soon after the onset of sexual activities.³ Worldwide HPV is associated with 50,000 new cases of cervical cancer and 250,000 associated cervical cancer deaths each year.³ Globally, HPV-16 and 18, the two vaccine-preventable types contribute to over 70% of all cervical cancer cases and after HPV-16/18, the six most common HPV types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an additional 20% of cervical cancers worldwide. World over about 569847 new cervical cancer cases are diagnosed annually and cervical cancer is the second most common female cancer in women aged 15 to 44 years.³ One woman dies of cervical cancer every 8 minutes in India. As per estimations for the year 2018, about 96922 new cervical cancer cases are diagnosed annually in India and here also it ranks as the second most common female cancer in all age groups.⁴ In the state of Himachal Pradesh, cancer cervix is a major public health problem since it ranked as the number one female cancer as per the annual reports of Regional Cancer Centre, Himachal Pradesh from 1998 to
2008, with around 250 cases being registered annually. Therefore all these data suggest that it is a global burden affecting every demographic region.

VACCINE RATIONALE

In brief HPV infection has a high burden on our society in terms of mortality and morbidity. Though chronic and cancerous diseases have multifactorial causation, and also numerous risk factors are known to be associated with cervical cancer etiology, HPV infection has emerged as the single most important causal factor. But being an infectious cause it is possible to contain its development and transmission. Coupled with this, we have a potent vaccine to fight this infection.

GLOBAL VACCINE STATUS

Similar to many infectious diseases effective vaccines are available for the control of this disease. In 2006, the FDA approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil, a quadrivalent vaccine. Cervarix, a bivalent vaccine marketed by GlaxoSmithKline was approved for use in the U.S. in October 2009. In December 2014, US FDA approved Gardasil 9 which is protective against nine serotypes. In April 2007, Australia became the first country to introduce a Government-funded National HPV Vaccination Program. By 2013, HPV vaccination has been introduced in about fifty countries around the globe with UK, USA, Australia, France, Germany, Italy, Japan, Norway, Sweden, Switzerland to name a few.

VACCINE EFFICACY

A comparative study on HPV-type prevalence in Pap smears in Australian women aged 18–24 years in the prevaccination period (2005–2007) and in the postvaccination period (2010–2011) using the same recruitment and testing strategies showed that the prevalence of vaccine HPV genotypes was significantly lower in the postvaccine sample than in the prevaccine sample (6.7 versus 28.7%; p<0.001). In USA, between the prevaccine and vaccine eras, HPV type prevalence declined from 11.5% to 4.3% among females aged 14 to 19 years and from 18.5% to 12.1% among females aged 20 to 24 years. Similarly global studies like PATRICIA trial and the FUTURE trial have equally proven vaccine efficacy. A well-documented account of positive impact of HPV vaccination has been published in numerous studies around the globe.

NATIONAL SCENARIO

As the data has been quoted earlier, India is not behind than rest of world in acquiring HPV infection and its chronic long term consequences. Recently, two HPV vaccination projects for operational feasibility were launched in Andhra Pradesh and Gujarat. However, the programs ran into controversy after alleged four deaths and complications among 120 girls were reported after vaccination and the program was terminated.

Apart from these controversies, a few other challenges are also there regarding implementation of vaccination program with the cost being the major obstacle. Speaking in monetary terms, bivalent vaccine costs around Rs. 3300 per dose while single dose of quadrivalent vaccine costs around Rs.2800. With multiple doses of both vaccines recommended in schedule the expense reaches even higher.

Furthermore in November 2016 Punjab became the first state in the country to include HPV vaccination in its universal immunization program with the assistance of World Health Organization country office for India. HPV vaccine has been rolled out in two districts and will subsequently be expanded to rest of the state. In phase one, close to 10 000 girls studying in class six of government schools were covered reflecting a 95% mobilization which shows enormous commitment.

RECOMMENDATIONS

Our country cannot sit back and let the limitations overpower the countermeasures. Controversies should not hinder the development of a well needed nationwide vaccination program. With better vaccines and safety trials the program should be reinitiated. And cost should not halt the development of this future as we are dealing in health and lives rather than going for earning profits. Strategies should be developed for bringing the cost down, like manufacturing of multi dose vials for mass vaccinations. Also Indian manufacturers can be encouraged to manufacture the vaccine and bulk purchases can be made from foreign suppliers. Assistance from agencies such as WHO can be sought like the help taken by the state of Punjab. Single dose vaccination can be implemented as it has been done countries like Costa Rica and found to be effective.

CONCLUSION

It's high time for India to launch an effective HPV vaccination program. A few hiccups here and there cannot halt the progress in this case. This era belongs to women empowerment and we cannot deny them the opportunity of good health. Simple and timely intervention like vaccination can save them from long term consequences and ensure the less expenditure on diagnostics and treatment in future. In nutshell, HPV related diseases are preventable and these should indeed be prevented.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required
REFERENCES


